Oncternal Therapeutics, Inc.: financial reference
Explore Oncternal Therapeutics, Inc. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.
Filing record ends 2024-03-07
The latest filing in this captured record is a 10-K filed 2024-03-07. No later filing is in the SEC companyfacts record captured on 2026-09-21. Oncternal Therapeutics, Inc. may have stopped filing, merged, or changed its reporting entity; nothing on this page describes its current status. Values are as reported at the time.
Reported financial histories
Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.
| Measure | Period start | Period end | Value | Unit | Filed |
|---|---|---|---|---|---|
| Total assets | At date | 2023-12-31 | 36,729,000 | USD | 2024-03-07 |
| Stockholders equity | At date | 2023-12-31 | 30,052,000 | USD | 2024-03-07 |
| Cash and cash equivalents | At date | 2023-12-31 | 6,697,000 | USD | 2024-03-07 |
| Net income or loss | 2023-01-01 | 2023-12-31 | -39,479,000 | USD | 2024-03-07 |
| Operating cash flow | 2023-01-01 | 2023-12-31 | -32,164,000 | USD | 2024-03-07 |
| Capital expenditure payments | 2017-01-01 | 2017-12-31 | 2,000 | USD | 2019-03-18 |
| Revenue | 2023-01-01 | 2023-12-31 | 785,000 | USD | 2024-03-07 |
| Financing cash flow | 2023-01-01 | 2023-12-31 | 1,068,000 | USD | 2024-03-07 |
| Investing cash flow | 2023-01-01 | 2023-12-31 | 651,000 | USD | 2024-03-07 |
| Retained earnings or deficit | At date | 2023-12-31 | -197,779,000 | USD | 2024-03-07 |
| Basic weighted-average shares | 2023-01-01 | 2023-12-31 | 2,940,000 | shares | 2024-03-07 |
| Diluted weighted-average shares | 2023-01-01 | 2023-12-31 | 2,940,000 | shares | 2024-03-07 |
| Basic earnings per share | 2023-01-01 | 2023-12-31 | -13.43 | USD/shares | 2024-03-07 |
| Diluted earnings per share | 2023-01-01 | 2023-12-31 | -13.43 | USD/shares | 2024-03-07 |
| Income tax expense or benefit | 2023-01-01 | 2023-12-31 | 0 | USD | 2024-03-07 |
| Net property, plant and equipment | At date | 2018-12-31 | 19,000 | USD | 2019-03-18 |
| Share-based compensation expense | 2023-01-01 | 2023-12-31 | 7,500,000 | USD | 2024-03-07 |
| Operating income or loss | 2023-01-01 | 2023-12-31 | -41,714,000 | USD | 2024-03-07 |
| Current assets | At date | 2023-12-31 | 36,059,000 | USD | 2024-03-07 |
| Current liabilities | At date | 2023-12-31 | 5,198,000 | USD | 2024-03-07 |
| Current accounts payable | At date | 2023-12-31 | 1,148,000 | USD | 2024-03-07 |
| Net finite-lived intangible assets | At date | 2018-12-31 | 94,000 | USD | 2019-03-18 |
| Net current accounts receivable | At date | 2012-12-31 | 9,000 | USD | 2013-03-05 |
| Operating expenses | 2023-01-01 | 2023-12-31 | 42,499,000 | USD | 2024-03-07 |
| Selling, general and administrative expense | 2011-01-01 | 2011-12-31 | 15,438,000 | USD | 2012-03-02 |
| Common shares outstanding | At date | 2023-12-31 | 2,948,000 | shares | 2024-03-07 |
| Cash including restricted cash | At date | 2018-12-31 | 28,258,000 | USD | 2019-03-18 |
| Additional paid-in capital | At date | 2023-12-31 | 227,825,000 | USD | 2024-03-07 |
| Accumulated other comprehensive income or loss | At date | 2023-12-31 | 3,000 | USD | 2024-03-07 |
| Operating lease right-of-use asset | At date | 2023-12-31 | 258,000 | USD | 2024-03-07 |
| Gross property, plant and equipment | At date | 2018-12-31 | 2,644,000 | USD | 2019-03-18 |
| Accumulated depreciation on property, plant and equipment | At date | 2018-12-31 | 2,625,000 | USD | 2019-03-18 |
| Other noncurrent assets | At date | 2023-12-31 | 412,000 | USD | 2024-03-07 |
| Other noncurrent liabilities | At date | 2014-12-31 | 30,000 | USD | 2016-03-15 |
| Accrued current liabilities | At date | 2023-12-31 | 3,877,000 | USD | 2024-03-07 |
| Prepaid expenses and other current assets | At date | 2023-12-31 | 1,804,000 | USD | 2024-03-07 |
| Net deferred tax assets | At date | 2023-12-31 | 66,628,000 | USD | 2024-03-07 |
| Pre-tax income or loss from continuing operations | 2014-01-01 | 2014-12-31 | -39,411,000 | USD | 2015-03-16 |
| Profit or loss including noncontrolling interests | 2023-01-01 | 2023-12-31 | -39,479,000 | USD | 2024-03-07 |
| Comprehensive income or loss | 2023-01-01 | 2023-12-31 | -39,485,000 | USD | 2024-03-07 |
| General and administrative expense | 2023-01-01 | 2023-12-31 | 12,746,000 | USD | 2024-03-07 |
| Depreciation expense | 2018-01-01 | 2018-12-31 | 32,000 | USD | 2019-03-18 |
| Depreciation, depletion and amortization | 2018-01-01 | 2018-12-31 | 46,000 | USD | 2019-03-18 |
| Other nonoperating income or expense | 2021-01-01 | 2021-12-31 | 33,000 | USD | 2022-03-10 |
| Proceeds from issuing common stock | 2023-01-01 | 2023-12-31 | 1,224,000 | USD | 2024-03-07 |
| Change in accounts receivable | 2012-01-01 | 2012-12-31 | -972,000 | USD | 2013-03-05 |
| Change in inventories | 2012-01-01 | 2012-12-31 | -133,000 | USD | 2013-03-05 |
| Change in accounts payable | 2023-01-01 | 2023-12-31 | -1,769,000 | USD | 2024-03-07 |
Filings
55 Oncternal Therapeutics, filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.
Inspect the source
- Entity
- Oncternal Therapeutics, Inc. / CIK 0001260990
- Captured
- 2026-09-21T17:18:09.927Z
- SEC response SHA-256
dcefea30a8ce148cff96c2a2fa09a3b61a34c7954f6f1a0e51956fda420a1d49
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001260990.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))